Bertech Pharma

Bertech Pharma is a Canadian biotechnology company based in Edmonton, Alberta, that specialized in developing targeted immunotherapies and diagnostics for oncology. The company's lead program, BP-01, is a monoclonal antibody designed to target GRP94 (glucose-regulated protein 94), an endoplasmic reticulum chaperone protein that is overexpressed on the surface of aggressive cancer cells. This target is particularly relevant for Triple-Negative Breast Cancer (TNBC), where GRP94 expression is associated with poor prognosis and increased metastasis. Bertech Pharma's approach focused on the dual utility of GRP94 as both a therapeutic target and a companion diagnostic biomarker to enable personalized medicine. While the company made progress in preclinical development, it is currently considered inactive.